Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 449778109 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Lundbeckfond Invest A/S 13D/A Amendment 2 | 27.4% |
6/2/2026
Event 3/31/2026
|
|
| Chernett Jorey 13G/A Amendment 2 | 0% |
5/20/2026
Event 3/31/2026
|
|
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
0% |
5/15/2026
Event 3/31/2026
|
|
| Point72 Asset Management, L.P. | 0% | ||
| Point72 Capital Advisors, Inc. | 0% | ||
| Steven A. Cohen | 0% | ||
| HBM Healthcare Investments (Cayman) Ltd. 13G/A Amendment 5 | 3.3% |
4/6/2026
Event 4/2/2026
|
|
| Chernett Jorey 13G/A Amendment 1 | 6.3% |
2/13/2026
Event 12/31/2025
|
|
|
Point72 Asset Management, L.P.
13G
|
5.6% |
2/6/2026
Event 2/5/2026
|
|
| Point72 Asset Management, L.P. | 5.6% | ||
| Point72 Capital Advisors, Inc. | 5.6% | ||
| Steven A. Cohen | 5.6% | ||
| Novo Holdings A/S 13D/A Amendment 8 | 3.3% |
1/23/2026
Event 1/21/2026
|
|
|
Vivo Capital IX, LLC
13G/A
Amendment 1
|
4.6% |
11/14/2025
Event 9/30/2025
|
|
| Vivo Capital IX, LLC | 0% | ||
| Vivo Capital Fund IX, L.P. | 0% | ||
| Vivo Opportunity, LLC | 4.6% | ||
| Vivo Opportunity Fund Holdings, L.P. | 4.6% | ||
| Chernett Jorey 13G | 5.3% |
11/5/2025
Event 10/30/2025
|
|
| Novo Holdings A/S 13D/A Amendment 7 | 7.3% |
8/19/2025
Event 8/11/2025
|
|
|
Samsara BioCapital, L.P.
13G/A
Amendment 1
|
3.8% |
2/14/2025
Event 12/31/2024
|
|
| Samsara BioCapital, L.P. | 3.8% | ||
| Samsara BioCapital GP, LLC | 3.8% | ||
| Srinivas Akkaraju | 3.8% | ||
| HBM Healthcare Investments (Cayman) Ltd. 13G/A Amendment 4 | 8.2% |
2/13/2025
Event 12/31/2023
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q1 | 12 | 3.39 M | $199 k |
| 2025 Q4 | 22 | 7.85 M | $4.78 M |
| 2025 Q3 | 21 | 9.90 M | $3.59 M |
| 2025 Q2 | 27 | 18.2 M | $25.3 M |
| 2025 Q1 | 23 | 19.1 M | $20.8 M |
| 2024 Q4 | 28 | 19.7 M | $18.2 M |
| 2024 Q3 | 21 | 23.6 M | $24.8 M |
| 2024 Q2 | 24 | 28.7 M | $33.6 M |
| 2024 Q1 | 22 | 31.8 M | $55.0 M |
| 2023 Q4 | 21 | 31.7 M | $59.6 M |
| 2023 Q3 | 21 | 29.7 M | $41.7 M |
| 2023 Q2 | 16 | 12.2 M | $24.0 M |
| 2023 Q1 | 18 | 13.9 M | $26.1 M |
| 2022 Q4 | 18 | 14.3 M | $32.8 M |
| 2022 Q3 | 22 | 15.3 M | $41.6 M |
| 2022 Q2 | 19 | 15.5 M | $72.2 M |
| 2022 Q1 | 20 | 14.9 M | $76.9 M |
| 2021 Q4 | 21 | 15.0 M | $92.6 M |